Abstract library

73 results for "Santos Fernández".
#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report
Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Rocío Morales Herrero
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#865 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study
Introduction: Hereditary Pheochromocytomas (PCC) and Paragangliomas (PGL) account for 30-35% of cases and have some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#991 Primary Neuroendocrine Tumor of Extrahepatic Bile Duct
Introduction: Biliary tract primary malignant tumors are rare neoplasms. Eighty-five per cent are cholangiocarcinomas, being in exceptional cases a neuroendocrine tumor. The absence of clinical suspiction involves a difficult preoperative diagnosis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Jose Angel Flores Garcia
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST
#1675 Abdominal Obesity, Fasting Glucose and Metabolic Syndrome Are Risk Factors for Well Differentiated Digestive Neuroendocrine Tumors
Introduction: Digestive NETs(DNETs)`s incidence has increased last 40 years. Visceral obesity and metabolic syndrome (MetSyn) were recently reported to be associated with several cancers, although not so far with DNET.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Ana Paula Santos
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#2992 The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project
Introduction: Neuroendocrine tumors are rare understudied diseases at the molecular level, especially those occurring in sites outside the lung and the gastrointestinal track. This lack of knowledge has strong implications for the clinical management of these diseases (Rindi et al. Mad Pathol 2018).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: PhD Lynnette Fernandez-Cuesta